Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics

mAbs

Volumn 6, Issue 4, 2014, Pages 957-967

  Wilmes, Gwendolyn M ^a   Carey, Kimberly L ^a   Hicks, Stuart W ^a   Russell, Hugh H ^a   Stevenson, Jesse A ^a   Kocjan, Paulina ^a   Lutz, Stephen R ^a   Quesenberry, Rachel S ^a   Shulga Morskoy, Sergey V ^a   Lewis, Megan E ^a   Clark, Ethan ^a   Medik, Violetta ^a   Cooper, Anthony B ^a   Reczek, Elizabeth E ^a  

^a Excelimmune Inc   (United States)

Author keywords

Adeno associated virus; Antibody cocktails; Antibody combination therapeutics; Antibody mixtures; Biologics expression; Monoclonal antibodies

Indexed keywords

ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY COMBINATION THERAPEUTICS; ANTIGEN SPECIFICITY; ARTICLE; CATION EXCHANGE; DRUG MIXTURE; GENE EXPRESSION SYSTEM; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MATRIX ATTACHMENT REGION; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; STABLE EXPRESSION; BIOSYNTHESIS; CELL LINE; COCULTURE; DEPENDOPARVOVIRUS; DRUG COMBINATION; GENE EXPRESSION; GENETICS; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; PROCEDURES;

CELL LINE; CHROMATOGRAPHY, ION EXCHANGE; COCULTURE TECHNIQUES; DEPENDOVIRUS; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HUMANS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84903755761     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28917     Document Type: Article

References (41)

1. Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. MAbs 2011; 3:338-51; PMID:21697653; http://dx.doi.org/10.4161/mabs.3. 4.16615
2. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922-7; PMID:18804136; http://dx.doi.org/10.1016/j.vaccine.2008.08.050
3. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr., Leney M, Sloan S, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205; PMID:20089970; http://dx.doi.org/10.1056/NEJMoa0907635
4. Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, et al. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem 2012; 421:351-61; PMID:22037290; http://dx.doi.org/10.1016/j.ab.2011.09. 030
5. Cheung GY, Otto M. The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections. Expert Opin Ther Targets 2012; 16:601-12; PMID:22530584; http://dx.doi.org/10.1517/14728222.2012.682573
6. Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 2012; 71:1741-8; PMID:22550316; http://dx.doi.org/10. 1136/annrheumdis-2011-201024
7. Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 2013; 31:1553-9; PMID:23370150; http://dx.doi.org/10.1016/j. vaccine.2013.01.025
8. Hiatt A, Zeitlin L, Whaley KJ. Multiantibody strategies for HIV. Clin Dev Immunol 2013; 2013:632893; PMID:23840243; http://dx.doi.org/10.1155/2013/632893
9. Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, Qiang J, Meng T, Goutama M, Kwang J. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 2009; 4:e5672; PMID:19478856; http://dx.doi.org/10.1371/ journal.pone.0005672
10. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006; 3:e237; PMID:16796401; http://dx.doi.org/10.1371/ journal.pmed.0030237
11. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-22; PMID:23103874; http://dx.doi.org/10.1038/nature11604
12. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 2005; 102:1915-20; PMID:15684082; http://dx.doi.org/10.1073/pnas. 0409610102
13. Marks JD. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 2004; 19(Suppl 8):S101-8; PMID:15027061; http://dx.doi.org/10.1002/mds.20023
14. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012; 12:397-407; PMID:22541629; http://dx.doi.org/10.1016/S1473-3099(11)70340-1
15. de Kruif J, Kramer A, Nijhuis R, van der Zande V, den Blanken R, Clements C, Visser T, Keehnen R, den Hartog M, Throsby M, et al. Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng 2010; 106:741-50; PMID:20564612; http://dx.doi.org/10.1002/bit.22763
16. Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics 2013; 10:1-18; PMID:23382582
17. Nielsen LS, Baer A, Müller C, Gregersen K, Mønster NT, Rasmussen SK, Weilguny D, Tolstrup AB. Single-batch production of recombinant human polyclonal antibodies. Mol Biotechnol 2010; 45:257-66; PMID:20306237; http://dx.doi.org/10.1007/s12033-010-9270-9
18. Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, Sharon J, Yang CY, Bregenholt S, Nielsen LS, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006; 94:396-405; PMID:16596663; http://dx.doi.org/10.1002/ bit.20865
19. Robak T, Windyga J, Trelinski J, von Depka Prondzinski M, Giagounidis A, Doyen C, Janssens A, Alvarez-Román MT, Jarque I, Loscertales J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012; 120:3670-6; PMID:22915649; http://dx.doi.org/10.1182/blood-2012-06-438804
20. Dorai H, Corisdeo S, Ellis D, Kinney C, Chomo M, Hawley-Nelson P, Moore G, Betenbaugh MJ, Ganguly S. Early prediction of instability of Chinese hamster ovary cell lines expressing recombinant antibodies and antibody-fusion proteins. Biotechnol Bioeng 2012; 109:1016-30; PMID:22068683; http://dx.doi.org/10.1002/ bit.24367
21. Barnes LM, Bentley CM, Dickson AJ. Stability of protein production from recombinant mammalian cells. Biotechnol Bioeng 2003; 81:631-9; PMID:12529877; http://dx.doi.org/10.1002/bit.10517
22. Nehlsen K, Schucht R, da Gama-Norton L, Krömer W, Baer A, Cayli A, Hauser H, Wirth D. Recombinant protein expression by targeting pre-selected chromosomal loci. BMC Biotechnol 2009; 9:100; PMID:20003421; http://dx.doi.org/10.1186/1472-6750-9-100
23. Henckaerts E, Linden RM. Adeno-associated virus: a key to the human genome? Future Virol 2010; 5:555-74; PMID:21212830; http://dx.doi.org/10.2217/ fvl.10.48
24. Hüser D, Gogol-Döring A, Lutter T, Weger S, Winter K, Hammer EM, Cathomen T, Reinert K, Heilbronn R. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 2010; 6:e1000985; PMID:20628575; http://dx.doi.org/10.1371/journal.ppat. 1000985
25. Janovitz T, Klein IA, Oliveira T, Mukherjee P, Nussenzweig MC, Sadelain M, Falck-Pedersen E. High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol 2013; 87:8559-68; PMID:23720718; http://dx.doi.org/10.1128/JVI.01135-13
26. Balagúe C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71:3299-306; PMID:9060699
27. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G. Adenoassociated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71:7951-9; PMID:9311886
28. Guilbaud M, Chadeuf G, Avolio F, François A, Moullier P, Recchia A, Salvetti A. Relative influence of the adeno-associated virus (AAV) type 2 p5 element for recombinant AAV vector site-specific integration. J Virol 2008; 82:2590-3; PMID:18094174; http://dx.doi.org/10.1128/JVI.01956-07
29. Philpott NJ, Giraud-Wali C, Dupuis C, Gomos J, Hamilton H, Berns KI, Falck-Pedersen E. Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J Virol 2002; 76:5411-21; PMID:11991970; http://dx.doi.org/10.1128/JVI.76.11.5411-5421.2002
30. Urabe M, Kogure K, Kume A, Sato Y, Tobita K, Ozawa K. Positive and negative effects of adenoassociated virus Rep on AAVS1-targeted integration. J Gen Virol 2003; 84:2127-32; PMID:12867644; http://dx.doi.org/10.1099/vir.0. 19193-0
31. Lai T, Yang Y, Ng SK. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel) 2013; 6:579-603; PMID:24276168; http://dx.doi.org/10.3390/ph6050579
32. Ye J, Alvin K, Latif H, Hsu A, Parikh V, Whitmer T, Tellers M, de la Cruz Edmonds MC, Ly J, Salmon P, et al. Rapid protein production using CHO stable transfection pools. Biotechnol Prog 2010; 26:1431-7; PMID:20564356; http://dx.doi.org/10.1002/btpr.469
33. Holmes D. Buy buy bispecific antibodies. Nat Rev Drug Discov 2011; 10:798-800; PMID:22037028; http://dx.doi.org/10.1038/nrd3581
34. Rasmussen SK, Næsted H, Müller C, Tolstrup AB, Frandsen TP. Recombinant antibody mixtures: production strategies and cost considerations. Arch Biochem Biophys 2012; 526:139-45; PMID:22820097; http://dx.doi.org/10.1016/ j.abb.2012.07.001
35. Rasmussen SK, Nielsen LS, Muller C, Bouquin T, Naested H, Monster NT, Nygaard F, Weilguny D, Frandsen TP, Tolstrup AB. Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes. BMC proceedings 2011; 5 Suppl 8:O2.
36. Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, Jensen AM, Persson P, Wikén M, Engström A, et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011; 108:2171-81; PMID:21495017; http://dx.doi.org/10.1002/bit.23166
37. Lamartina S, Roscilli G, Rinaudo D, Delmastro P, Toniatti C. Lipofection of purified adeno-associated virus Rep68 protein: toward a chromosome-targeting nonviral particle. J Virol 1998; 72:7653-8; PMID:9696870
38. Howden SE, Voullaire L, Vadolas J. The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration. J Gene Med 2008; 10:42-50; PMID:18001001; http://dx.doi.org/10.1002/jgm.1118
39. Poste G, Doll J, Fidler IJ. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A 1981; 78:6226-30; PMID:6947225; http://dx.doi.org/10.1073/pnas.78.10.6226
40. Philpott NJ, Gomos J, Berns KI, Falck-Pedersen E. A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci U S A 2002; 99:12381-5; PMID:12221283; http://dx.doi.org/10.1073/pnas.182430299
41. Pörtner R. Animal cell biotechnology: methods and protocols. Totowa, NJ: Humana Press, 2007.